Nuvation Bio Inc. (NUVB) Stock

Nuvation Bio Inc. (NUVB) is a Healthcare stock trading at $6.92 (as of 2026-08-21), with a market capitalization of $2.43B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company developing therapeutic candidates in oncology, including small-molecule programs such as NUV-422 and other drug candidates targeting pathways involved in tumor growth and DNA damage response. It also develops a drug-drug conjugate platform using PARP inhibitor-based warheads for anti-cancer applications.

Understand Nuvation Bio Inc.: how it makes money

Nuvation Bio Inc. is a clinical-stage oncology biopharmaceutical company that develops targeted small molecule therapies (including NUV-422) and also generates revenue from its Ibtrozi product, with money coming from collaboration and license agreements as well as Ibtrozi net product sales.

The profit engine is monetizing Ibtrozi through net product revenue, supported by collaboration and license agreement revenue, rather than relying on pipeline programs alone.

Revenue by segment (latest quarter)
Collab$0.1B
Ibtrozi$0.0B
Ibtrozi US$0.0B

Business quality (Weak): Revenue mix shows some commercialization (Ibtrozi) alongside collaboration and license revenue, but key operating visibility depends on patient starts and the durability of clinical response.

Bull case

  • Ibtrozi shows measurable commercial traction, with Ibtrozi Net Product Revenue contributing 0.02 B to the latest-quarter revenue base: This suggests the business has started to generate product cashflow, not only development-stage exposure.
  • Clinical performance in the TRUST-II Cohort is strong, with a Confirmed Overall Response Rate (TRUST-II Cohort) of 80.0 percent: High response rates can support ongoing clinical and commercial momentum for a targeted oncology therapy.

Bear case

  • Commercial scaling risk, patient funnel dynamics matter because Ibtrozi New Patient Starts are tracked as an operating metric: If new patient starts slow, net product revenue (and overall revenue) may be pressured even if collaborations continue.
  • Dependence on non-product funding streams, with Collaboration and License Agreements Revenue of 0.06 B in the latest quarter: If collaboration timing changes, revenue support could be less predictable.
Valuation — source: SEC EDGAR (first-party)
Price$6.92
Market Cap$2.43B
Price / Book9.58
Price / Sales11.51
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$62.90M
Net Margin-325.3%
Revenue Growth (YoY)699.0%
EPS Growth (YoY)-71.6%
Financial Health — source: SEC EDGAR
Altman Z-Score2.14 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($223.04M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid T. Hung
Employees273
CountryUS
IPO Date2020-08-26

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Fortress Biotech, Inc. (FBIO)
  • Tango Therapeutics, Inc. (TNGX)
  • Journey Medical Corporation (DERM)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Aytu BioPharma, Inc. (AYTU)
  • Kura Oncology, Inc. (KURA)
  • Rockwell Medical, Inc. (RMTI)
  • Nektar Therapeutics (NKTR)
NUVB earnings history · NUVB institutional & insider holders · NUVB KPIs & operating metrics · NUVB financials · NUVB investor presentations & press releases · NUVB SEC filings · NUVB peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.